Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | PRF1 | P14222 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22981715 | 0.88 | MEN1 (0.49) | GRM5MEN1KMT2A | |
| SCHEMBL29405544 | 0.88 | MEN1 (0.49) | GRM5MEN1KMT2A | |
| SCHEMBL16456387 | 0.86 | GRM5 (0.54) | GRM5AOC3MEN1KMT2AOPRD1 | |
| SCHEMBL18865654 | 0.84 | GRM5 (0.52) | GRM5AOC3MEN1KMT2AOPRD1 | |
| SCHEMBL25188872 | 0.84 | GRM5 (0.52) | GRM5AOC3MEN1KMT2AOPRD1 | |
| SCHEMBL4598160 | 0.84 | EGFR (0.43) | PRF1CHKA | |
| SCHEMBL30149709 | 0.84 | EGFR (0.43) | PRF1CHKA | |
| SCHEMBL18713751 | 0.83 | GRM5 (0.51) | GRM5AOC3MEN1KMT2AOPRD1 | |
| SCHEMBL1115278 | 0.82 | ITGB3 (0.46) | GRM5MEN1KMT2AOPRD1ITGB3 | |
| SCHEMBL24253347 | 0.82 | GRM5 (0.50) | GRM5AOC3MEN1KMT2AOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741386-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20250034133-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2025-01-30 | — | — | US | disclosed |
| CN-119173512-A | Small molecule inhibitors of ubiquitin-specific protease 1 (USP 1) and uses thereof | 英矽智能科技知识产权有限公司 | 2024-12-20 | — | — | CN | disclosed |
| EP-4430041-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2024-09-18 | — | — | EP | disclosed |
| CN-118660872-A | Pyrimidine compound, preparation method and medical application thereof | 江苏亚虹医药科技股份有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| CN-116496252-A | Pyrimidine compound, preparation method and medical application thereof | 江苏亚虹医药科技股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| WO-2023083297-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-19 | — | — | WO | disclosed |
| WO-2021028645-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028649-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| EP-2683710-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INT (DE) | 2017-07-19 | — | — | EP | disclosed |
| EP-2683710-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Boehringer Ingelheim International GmbH (DE) | 2014-01-15 | — | — | EP | disclosed |
| US-8569339-B2 | Soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569339-B2 | Soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| WO-2012122340-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012122340-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | GRM5 3607/4885AOC3 591/4885MEN1 602/4885 |
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A1, GUCY1A2, GUCY1B1 | GRM5 2059/4885AOC3 2641/4885MEN1 843/4885 |
| US-20250034133-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | USP1, USP2, USP28 | GRM5 4214/4885AOC3 2959/4885MEN1 1722/4885 |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | GRM5 3443/4885AOC3 3417/4885MEN1 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.